文献速递肺结节与肺癌

利物浦肺癌项目风险分层模型的校准与前瞻性验证

Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation.
PubMed 文献 · Thorax · 2020-10-20

两版模型ROC曲线下面积均为0.81(95%CI 0.79-0.82),但LLPv2高估绝对风险,比例差异为-58.3%;经2017年全国数据校准的LLPv3比例差异改善至-22.0%,绝对风险预测更优。

要点

  • LLPv2与LLPv3判别力相同,ROC曲线下面积均为0.81。
  • LLPv2高估绝对风险,实际癌症数仅为预测数的42%。
  • LLPv3校准后比例差异为-22.0%,绝对风险预测改善。

核心结论

  • LLPv2与LLPv3判别力相同,但LLPv3改善了绝对肺癌风险预测,应考虑用于进一步的英国实施研究。

研究设计与样本

  • 基于利物浦病例对照数据开发LLPv2并用于英国肺癌筛查试验受试者选择,经2017年全国数据校准产生LLPv3。

主要发现

  • 5年内诊断599例肺癌。
  • LLPv2和LLPv3的ROC曲线下面积均为0.81(95%CI 0.79-0.82)。
  • LLPv2高估绝对风险,比例差异为-58.3%(95%CI -61.6%至-54.8%),实际癌症数为预测数的42%。
  • LLPv3(经2017年全国数据校准)比例差异为-22.0%(95%CI -28.1%至-15.5%)。

临床怎么用

  • LLPv3可用于英国进一步实施研究中肺癌高风险人群的绝对风险预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early detection of lung cancer saves lives, as demonstrated by the two largest published low-dose CT screening trials. Optimal implementation depends on our ability to identify those most at risk. METHODS: Version 2 of the Liverpool Lung Project risk score (LLPv2) was developed from case-control data in Liverpool and further adapted when applied for selection of subjects for the UK Lung Screening Trial. The objective was to produce version 3 (LLPv3) of the model, by calibration to national figures for 2017. We validated both LLPv2 and LLPv3 using questionnaire data from 75 958 individuals, followed up for lung cancer over 5 years. We validated both discrimination, using receiver operating characteristic (ROC) analysis, and absolute incidence, by comparing deciles of predicted incidence with observed incidence. We calculated proportionate difference as the percentage excess or deficit of observed cancers compared with those predicted. We also carried out Hosmer-Lemeshow tests. RESULTS: There were 599 lung cancers diagnosed over 5 years. The discrimination of both LLPv2 and LLPv3 was significant with an area under the ROC curve of 0.81 (95% CI 0.79 to 0.82). However, LLPv2 overestimated absolute risk in the population. The proportionate difference was -58.3% (95% CI -61.6% to -54.8%), that is, the actual number of cancers was only 42% of the number predicted.In LLPv3, calibrated to national 2017 figures, the proportionate difference was -22.0% (95% CI -28.1% to -15.5%). CONCLUSIONS: While LLPv2 and LLPv3 have the same discriminatory power, LLPv3 improves the absolute lung cancer risk prediction and should be considered for use in further UK implementation studies.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Field JK, Vulkan D, Davies MPA, et al. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. Thorax. 2020. PMID: 33082166. doi:10.1136/thoraxjnl-2020-215158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。